Hebei General Hospital Shijiazhuang, Shijiazhuang, Hebei, 050000, China.
Graduate School of Hebei North College Zhangjiakou, Zhangjiakou, Hebei, 075000, China.
Invest New Drugs. 2023 Dec;41(6):787-790. doi: 10.1007/s10637-023-01401-3. Epub 2023 Oct 13.
Pulmonary enteric adenocarcinoma (PEAC) is a rare lung adenocarcinoma with morphological and immunohistochemical similarities to colorectal adenocarcinoma and intestinal differentiation. PEAC belongs to the group of non-small-cell lung carcinoma (NSCLC) and is defined as having a more than 50% intestinal differentiation component. We report a postoperative (T4N2M0 stage IIIb) PEAC patient with EGFR L858R + A871G combined mutation. Following surgery, the patient underwent treatment with the first-generation EGFR-TKI, gefitinib, and achieved an impressive 5-year progression-free survival (PFS). This suggests that gefitinib may serve as an effective treatment option for PEAC patients with EGFR L858R + A871G compound mutations.
肺肠型腺癌（PEAC）是一种罕见的肺腺癌，其形态学和免疫组织化学特征与结直肠腺癌和肠分化相似。PEAC 属于非小细胞肺癌（NSCLC）的范畴，其定义为具有超过 50%肠分化成分。我们报告了一例术后（T4N2M0 Ⅲb 期）具有 EGFR L858R+A871G 复合突变的 PEAC 患者。术后，该患者接受了第一代 EGFR-TKI，吉非替尼治疗，并获得了令人瞩目的 5 年无进展生存期（PFS）。这表明吉非替尼可能是具有 EGFR L858R+A871G 复合突变的 PEAC 患者的有效治疗选择。
